July 13 (Reuters) - Nuvo Pharmaceuticals Inc NRI.TO
* Topline results of trial are expected to be available in
late Q2 or early Q3 2017
* Nuvo Pharmaceuticals Inc announces Pennsaid 2% phase 3
trial to support regulatory approvals in the E.U., Canada and
Australia
* Nuvo Pharmaceuticals Inc says trial will cost
approximately cdn$1.5 million spread over second half of 2016
and first half of 2017
Source text for Eikon: ID:nCNWvwGR1a
Further company coverage: NRI.TO